Polo-Like Kinase 2-Dependent Phosphorylation of NPM/B23 on Serine 4 Triggers Centriole Duplication by Krause, Annekatrin & Hoffmann, Ingrid
Polo-Like Kinase 2-Dependent Phosphorylation of NPM/
B23 on Serine 4 Triggers Centriole Duplication
Annekatrin Krause, Ingrid Hoffmann*
Cell Cycle Control and Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany
Abstract
Duplication of the centrosome is well controlled during faithful cell division while deregulation of this process leads to
supernumary centrosomes, chromosome missegregation and aneuploidy, a hallmark of many cancer cells. We previously
reported that Polo-like kinase 2 (Plk2) is activated near the G1/S phase transition, and regulates the reproduction of
centrosomes. In search for Plk2 interacting proteins we have identified NPM/B23 (Nucleophosmin) as a novel Plk2 binding
partner. We find that Plk2 and NPM/B23 interact in vitro in a Polo-box dependent manner. An association between both
proteins was also observed in vivo. Moreover, we show that Plk2 phosphorylates NPM/B23 on serine 4 in vivo in S-phase.
Notably, expression of a non-phosphorylatable NPM/B23 S4A mutant interferes with centriole reduplication in S-phase
arrested cells and leads to a dilution of centriole numbers in unperturbed U2OS cells. The corresponding phospho-
mimicking mutants have the opposite effect and their expression leads to the accumulation of centrioles. These findings
suggest that NPM/B23 is a direct target of Plk2 in the regulation of centriole duplication and that phosphorylation on serine
4 can trigger this process.
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Introduction
Centrosomes play fundamental roles in regulating chromosome
segregation in mitosis and the interphase microtubule cytoskele-
ton. The centrosome consists of a pair of centrioles surrounded by
amorphous pericentriolar material. Like chromosomes, the
centrioles duplicate only once per cell cycle. Centriole duplication
is initiated at the G1/S boundary and is completed in S-phase of
the cell cycle, which coincides with DNA replication [1].
Interestingly, there is a correlation between excess centrosomes,
aneuploidy, and cancer [2]. Errors in centriole duplication lead to
cells with too many or too few centrosomes; the resulting
monopolar spindles or bipolar spindles, which harbor clustered
centrosomes at their spindle poles, disrupt chromosome segrega-
tion and can lead to genomic instability [3]. Therefore, extra
centrosomes alone are sufficient to promote chromosome
missegregation during bipolar cell division. Thus, understanding
regulatory mechanisms governing centrosome duplication pro-
vides insights into both normal cell behavior and tumorigenesis.
Several human protein kinases were shown to be critical for
centriole duplication and assembly. The duplication of the
centrosome is initiated by the disengagement of the two centrioles
at the end of mitosis [4]. This is followed by an activation of Polo-
like kinase 4 (Plk4) and the subsequent recruitment of hSAS-6 and
other centriolar components to maternal centrioles, which are
critical steps in procentriole assembly [5]. In addition, Plk2 is
localized to centrosomes and its kinase activity is also required for
centriole duplication [6][7]. Plk2 substrates in this process are
currently unknown. Plk2 and Plk4 exhibit distinct structural
properties especially at the Polo-box domains (PBD) and have
their own substrate specificities consequently [8][9]. Cdk2 is also
necessary for initiation of centriole duplication [10]. A few
candidate substrates were identified as being responsible for
Cdk2 function in centrosome duplication. For example, Cdk2
phosphorylates NPM/B23 (Nucleophosmin) [11] on threonine (T)
199 resulting in its dissociation from the centrosome prior to the
initiation of centriole duplication [12]. These results suggest that
NPM/B23 may negatively regulate this process. NPM/B23
reassociates with centrosomes during mitosis [11] [13]. Phospho-
protein profiling of M-phase arrested cells by nocodazole
treatment also shows that NPM/B23 is phosphorylated in mitosis
on serine (S) 4 which is dependent on Polo-like kinase 1 (Plk1) [14].
NPM/B23 is a multifunctional protein that is involved in a
number of cellular activities. It has been related to both growth-
suppressive and proliferative roles in the cell. A large fraction of
NPM/B23 resides in the nucleoli, although it shuttles rapidly
between the nucleus and the cytoplasm [15]. On the one hand,
NPM/B23 is frequently overexpressed in solid tumors of diverse
histological origin, whereas on the other hand, the NPM1 locus is
involved in chromosomal translocations or deleted in various kinds
of haematological malignancies and solid tumors [16]. NPM1 is
essential for embryonic development and the maintenance of
genomic stability in mice. Interestingly, NPM1 inactivation leads to
unrestricted centrosome duplication, and supernumary centro-
somes were observed [17].
To find substrates of Plk2 kinase in centrosome duplication we
used a biochemical approach and identified NPM/B23. We show
that Plk2 interacts with and phosphorylates NPM/B23 on S4 in
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9849both mitosis and S-phase while Plk1 seems to be involved only in
its mitotic phosphorylation. Furthermore, we demonstrate that
Plk2-dependent phosphorylation of NPM/B23 on S4 triggers both
centriole reduplication and normal centrosome reproduction. Our
results suggest that Plk2 exerts its role in centrosome duplication
by phosphorylating NPM/B23 on S4.
Results
Identification of NPM/B23 as a novel Plk2 binding partner
To identify Plk2 interacting proteins and potential substrates,
we transfected an EGFP-tagged Plk2 kinase-inactive mutant (Plk2
KD) into HeLa cells and immunoprecipitated the proteins by
using anti-GFP antibodies. We used a kinase-inactive mutant since
it stabilizes the interaction with substrates. Several interacting
bands could be identified that were absent in the control
immunoprecipitation (Fig. 1A). These bands were subjected to
mass spectrometry analysis where a band, migrating at 35 kDa,
was identified as NPM/B23 (Nucleophosmin) (Fig. 1B). The
interaction was verified in a pulldown assay using purified
recombinant Zz-tagged kinase active Plk2 (Plk2 WT) or KD
bound to IgG sepharose that was incubated with a HeLa cell
lysate. Interacting proteins were eluted under low and high salt
(NaCl) conditions and then subjected to Western blot analysis.
Fig. 1C shows that NPM/B23 bound to both Plk2 WT and Plk2
KD. We further tested the interaction between NPM/B23 and
Plk2 by co-immunoprecipitation assays using either co-transfection
of Flag-NPM/B23 and Myc-Plk2 KD or transfection of Myc-Plk2
KD alone into 293T cells. Anti-Flag antibodies co-immunopre-
cipitated Plk2 (Fig. 2A) and anti-Myc antibodies co-immunopre-
cipitated endogenous NPM/B23 (Fig. 2B) demonstrating the
physical interaction between these two proteins. To verify that
Plk2 and NPM/B23 interact in vivo Plk2 was immunoprecipitated
from HeLa cell lysates with specific antibodies [6]. Using NPM/
B23 antibodies in the following immunoblot we detected an
interaction between endogenous proteins in vivo (Fig. 2C).
As the conserved Polo-boxes of most Plks are required for their
function and interaction with substrates [18], we asked the
question if binding between NPM/B23 and Plk2 is mediated
through the Polo-box domain (PBD) of Plk2. We used a Far
Western ligand binding assay to test the ability of the PBD to bind
NPM/B23. The assay was carried out using recombinant NPM/
B23 with either GST, GST-PBD, or GST-PBD-mutant [7].
Ligand-binding was analyzed with anti-GST antibodies. Fig. 2D
shows that GST-PBD bound to NPM/B23 while no binding was
observed when GST-alone was incubated with NPM/B23. In
addition, reduced binding was observed in comparison to the
wildtype when GST-PBD-mutant was used. These results suggest
that the PBD domain of Plk2 is required for the binding to NPM/
B23. Next, to identify the essential region of Plk2 required for the
interaction with NPM/B23, we generated Flag-tagged Plk2
truncated versions (Fig. 2E) that were ectopically expressed in
Figure 1. Identification of NPM/B23 as Plk2 interacting partner. A EGFP-tagged Plk2 kinase dead (KD, N210A) or EGFP alone, overexpressed
in HeLa cells, was immunoprecipitated by anti-GFP antibodies and immunocomplexes were resolved by SDS-PAGE. Co-immunoprecipitating proteins
were detected by silver staining. The co-precipitating protein NPM/B23 was identified by mass spectrometry analysis of a protein band with an
approximate size of 35 kDa. IgG bands are marked with asterisks (*). B Mass spectrometry analysis results of two independent EGFP-Plk2 KD
immunoprecipitations where NPM/B23 was identified as a Plk2 interaction partner. C Zz-Plk2 wildtype (WT), KD or Zz alone as control were bound to
IgG sepharose and incubated with HeLa lysate. After washing protein complexes, interacting proteins were eluted under low (200 mM NaCl) or high
salt (1 M NaCl) conditions and analyzed by SDS-PAGE and Western blotting using anti-Plk2 and anti-NPM/B23 antibodies.
doi:10.1371/journal.pone.0009849.g001
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noprecipitates were then incubated with purified recombinant His-
tagged NPM/B23. As clearly shown in Fig. 2F Flag-Plk2-(amino
acids (aa) 340–685) and Flag-Plk2-(aa 590–685) efficiently bound
to NPM/B23 implying that the region between amino acid
residues 340 and 585 of Plk2, harboring the C-terminal regulatory
part of the kinase, is important for the interaction with NPM/B23.
Moreover, since Flag-Plk2-(aa 590–685), comprising only the
second Polo-box, bound NPM/B23 as efficiently as the longer
Flag-Plk2-(aa 340–685) fragment, the second Polo-box of Plk2
seems to be sufficient for the interaction with NPM/B23. Since
Plk2 binds to unphosphorylated, bacterially produced NPM/B23
in these experiments, a pre-phosphorylation event by an additional
kinase might not be required for the PBD-dependent interaction
between Plk2 and NPM/B23. However, a self-priming mechanism
as described previously for Plk1 and PBIP1 [19] might strengthen
the physical interaction between NPM/B23 and Plk2. Vice versa,
to map the Plk2-interacting domain on NPM/B23 we constructed
GST-tagged deletion mutants including NPM/B23-(aa 1–120),
NPM/B23-(aa 1–220), NPM/B23-(aa 120–294) and NPM/B23-
(aa 220–294) (Fig. 2G). We then tested the interaction between
Plk2 and each of these NPM/B23 deletion mutants. A GST-
pulldown assay was used to identify the domain of NPM/B23
necessary for binding to in vitro translated [
35S]-HA-Plk2. We
found that NPM/B23-(aa 120–294) and NPM/B23-(aa 220–294)
retained the ability to bind to Plk2, whereas NPM/B23-(aa 1–120)
and NPM/B23-(aa 1–220) did not. These results indicate that
NPM/B23 physically interacts with Plk2 through its amino acid
residues 220–294 (Fig. 2H). Since we have shown that Plk2
interacts with NPM/B23 through its PBD (Fig. 2D), we asked
whether the localization of Plk2 at the centrosome would be
impaired when NPM/B23 is absent. We find that down-regulation
of NPM/B23 by siRNAs to ,20% but not control siRNAs (Fig. 2I,
left) leads to marked loss of the Plk2 signal at the centrosomes
(Fig. 2I, middle and right) which suggests that NPM/B23 recruits
Plk2 to the centrosome most likely through binding to the PBD of
Plk2.
Plk2 directly phosphorylates serine 4 on NPM/B23
Furthermore, to address whether Plk2 could phosphorylate
NPM/B23, we carried out in vitro kinase reactions. Flag-NPM/B23
was transfected into 293T cells, immunoprecipitated with Flag-
antibodies and then incubated with Zz-Plk2 WT and Zz-Plk2 KD
as control in the presence of [c
32P]-ATP. The reaction mixtures
were separated by SDS–PAGE and subjected to autoradiography
(Fig. 3A). The results showed that Plk2 phosphorylates NPM/B23
in vitro. To identify the Plk2 phosphorylation site on NPM/B23, we
first determined the region in the NPM/B23-protein that is
phosphorylated by Plk2. For this, NPM/B23 deletion mutants
(Fig. 2G) were used in an in vitro kinase assay with active
recombinant Zz-Plk2. Results in Fig. 3B reveal that in vitro
phosphorylation occurs in the deletion mutants NPM/B23-(aa 1–
120) and NPM/B23-(aa 1–220). A slight phosphorylation was also
detected in NPM/B23-(aa 120–294) (Fig. 3B). To identify Plk2
specific phosphorylation sites we mutated several S and T amino
acid residues within the amino acid region 1 to 125 in NPM/B23.
These comprise S4 [14], T95 [15], T199 [12] and S125. We
included the fragment containing S125 in our analysis since the
region surrounding S125 ressembles a putative Plk2 phosphory-
lation site [20]. To show which sites are phosphorylated by Plk2,
we first generated GST-tagged N-terminal (aa 1–120) fragments
where S4 and T95 were mutated to alanine (A). Both purified
fragments were subjected along with the WT fragment to in vitro
kinase assays using active Zz-tagged Plk2 WT. While the fragment
containing the T95A mutant was still phosphorylated to a similar
extent as the WT fragment, no incorporation of phosphate was
observed when S4 was mutated to alanine (Fig. 3C). Mutation of
the putative Plk2 consensus site S125 to alanine still resulted in
incorporation of [c
32P] into NPM/B23 suggesting that this site is
not phosphorylated by Plk2 (Fig. 3D). Then we tested phosphor-
ylation deficient mutants of full-length NPM/B23 WT, S4A and
T199A, upon phosphorylation by Plk2. We expressed the
constructs in 293T cells, immunoprecipitated the proteins with
anti-Flag-antibodies and subjected the immunoprecipitates to an in
vitro kinase assay with recombinant Zz-tagged Plk2. While [c
32P]
was efficiently incorporated in both NPM/B23 WT and the
T199A mutant, the NPM/B23 S4A mutant was not phosphor-
ylated by Plk2 (Fig. 3E) confirming that S4 is the site that is
phosphorylated by Plk2. To further verify that NPM/B23 is
phosphorylated by Plk2 on S4 we used a phospho-specific
antibody against NPM/B23 phosphorylated on S4 (pS4 NPM/
B23) in a reaction where His-tagged NPM/B23 WT or NPM/B23
S4A was incubated with Plk2 WT or KD in an in vitro kinase assay.
Fig. 3F shows that the NPM/B23 S4A-mutant cannot be
phosphorylated by active Plk2. Similar to Plk2, Plk1 is also able
to phosphorylate NPM/B23 on S4 (Fig. 3G and [14]). Together,
these results show that NPM/B23 is phosphorylated on S4 by both
Plk2 and Plk1 in vitro.
Plk-dependent phosphorylation of NPM/B23 is cell cycle-
regulated
The activity profiles of Plk1 and Plk2 are different during the
cell cycle. Plk1 is activated near the G2/M phase transition until
the end of cytokinesis [21] while Plk2 is activated in G1 near the
G1/S phase transition [6]. We therefore determined the
phosphorylation profile of NPM/B23 on S4 during the cell cycle
Figure 2. Plk2 interacts with NPM/B23 in vivo and in vitro.AAfter overexpression of Myc-Plk2 KD and Flag-NPM/B23 in 293T cells, cell extracts
were subjected to immunoprecipitations using anti-Flag antibodies. Co-precipitation of Myc-Plk2 KD by Flag-NPM/B23 was detected by Western
blotting using anti-Plk2 and anti-NPM/B23 antibodies. Asterisks (*), endogenous NPM/B23. B Myc-Plk2 KD was overexpressed in 293T cells and
immunoprecipitated with anti-Myc antibodies. Complex formation of Myc-Plk2 KD and endogenous NPM/B23 was analyzed by Western blot with
anti-Plk2 and anti-NPM/B23 antibodies. C Endogenous Plk2 was immunoprecipitated from HeLa lysates by specific antibodies. The interaction was
verified by Western blotting using anti-NPM/B23 and anti-Plk2 antibodies. IgG, random antibody control. D Far Western blot analysis. Recombinant
His-tagged NPM/B23 was resolved by SDS-PAGE, blotted onto nitrocellulose and incubated with GST-Plk2 PBD, -PBD mutant or GST (control) to allow
interaction. Protein bound to NPM/B23 was detected with anti-GST antibodies. Equal amounts of GST-PBD, -PBD mutant and GST used for ligand
binding are demonstrated by Coomassie blue staining. E Scheme of Plk2 truncated versions. F Flag-Plk2 truncated versions (E) were overexpressed in
293T cells, immunoprecipitated by anti-Flag antibodies and incubated with recombinant His-NPM/B23 in in vitro binding assays. Complexes were
separated by SDS-PAGE and analyzed by Western blot using anti-NPM/B23 and anti-Flag antibodies. G Scheme of NPM/B23 truncated versions. H
Glutathione sepharose-bound GST-NPM/B23 truncated versions (G) or GST (control) were incubated with in vitro translated, [
35S]-methionine-labeled
HA-Plk2 in pull down assays. Complexes were resolved by SDS-PAGE. After Coomassie blue staining, interactions were detected by autoradiography. I
NPM/B23 was downregulated by siRNA in U2OS cells as demonstrated in a Western blot analysis (left panel). Indirect immunofluorescence analysis
was performed for Plk2 (red) and centriolar GT335 (green) (middle panel). Localization of centriolar Plk2 was quantified in 3 independent experiments
with .150 analyzed cells each (right panel). GL2, siRNA control; loading control, a-Tubulin.
doi:10.1371/journal.pone.0009849.g002
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mitosis. While S4 was heavily phosphorylated in M-phase, a slight
but distinct phosphorylation of this site also occurs in S-phase
(Fig. 4A). We then compared the kinase activities of Plk1 and Plk2
that were immunoprecipitated from cells arrested in S-phase
(hydroxyurea block) or pro-metaphase (nocodazole block) on a-
Casein or His-NPM/B23 as substrate. While active Plk1 could
only be immunoprecipitated from M-Phase, Plk2 immunoprecip-
itates were active in both M- and S-phases on both a-Casein
(Fig. 4B) and His-tagged NPM/B23 (Fig. 4C) as substrates. Since
Plk2 but not Plk1 is active in S-phase (Fig. 4B and 4C) [21] [6] the
phosphorylation of NPM/B23 on S4 in S-phase accounts for a
dependency on Plk2 activity at this cell cycle stage. To further
demonstrate the involvement of both Plk1 and Plk2 in the
regulation of NPM/B23 S4 phosphorylation we made use of the
small molecule inhibitor, BI2536 that inhibits both Plk1 and Plk2
kinase activities [22]. We tested the effect of inhibiting Plk1 and
Plk2 kinases by BI2536 in in vitro kinase assays using the pS4
NPM/B23 antibody. Both Plk1 (Fig. 4D) and Plk2 kinase activities
(Fig. 4E) were inhibited in their abilities to phosphorylate NPM/
B23 on S4 in vitro. To assess the inhibitory effect of BI2536 on Plk1
and Plk2 in vivo, HeLa cells were treated with BI2536 and Plk1 and
Plk2 were immunoprecipitated by specific antibodies and
subjected to a kinase assay with a-Casein as exogenous substrate.
As shown in Fig. 4F, both Plk1 and Plk2 can be partially inhibited
by BI2536 in vivo, but Plk1 was inhibited to a stronger extent. To
analyze the effect of BI2536 on the NPM/B23 S4 phosphoryla-
tion, exponentially growing U2OS and HeLa cells were treated
with BI2536 and analyzed consequently in a Western blot for pS4
NPM/B23 levels. In both cell lines, BI2536 treatment led to a
decrease in pS4 NPM/B23 levels (Fig. 4G). Since Plk1 is not active
in S-phase but Plk2 is, the effect of BI2536 on S4 phosphorylation
of NPM/B23 was also investigated in S-phase arrested HeLa cells.
As shown in Fig. 4G, BI2536 treatment also results in a decrease of
pS4 NPM/B23 levels in S-phase cells. Taken together, phosphor-
ylation of NPM/B23 S4 can be mediated by both Polo-like
kinases, Plk1 and Plk2 (Fig. 4D–G). However, since both kinases
display differential activities during the cell cycle (Fig. 4B and 4C),
a phosphorylation of NPM/B23 by Plk1 is suggested for mitosis
while a phosphorylation of NPM/B23 on S4 in S-phase is likely to
be catalyzed by Plk2.
Phosphorylation on S4 of NPM/B23 is dependent on Plk2
in S-phase
To directly confirm that NPM/B23 is phosphorylated by Plk2
in S-phase HeLa cells were transfected with either Flag-tagged
Plk2 WT or Plk2 KD and then treated with hydroxyurea (HU) to
arrest cells in early S-phase. Western blot analysis shows that
phosphorylation of NPM/B23 on S4 is increased upon Plk2 WT
transfection while Plk2 KD expression decreased the signal in
comparison to non-transfected control cells most likely by
competing out the endogenous active Plk2 (Fig. 5A). To confirm
these data we depleted Plk2 by RNAi using shRNA-treatment [6].
As shown in Fig. 5B the phosphorylated NPM/B23-S4 signal was
reduced in both asynchronous and HU-treated 293T cells
suggesting that Plk2 is regulating S4 phosphorylation in vivo.
Although Plk1 is not active in S-phase (Fig. 4B and 4C), low
protein levels of Plk1 are detectable in this cell cycle stage (Fig. 5C).
To rule out, that these residual amounts of Plk1 are responsible for
a NPM/B23 S4 phosphorylation in S-phase, Plk1 was depleted
from S-phase arrested HeLa cells by siRNA transfections and
analyzed for pS4 NPM/B23 levels. Fig. 5C reveals that a
downregulation of Plk1 in S-phase arrested cells did not affect
pS4 NPM/B23 protein levels. This again shows that a S-phase
linked phosphorylation of NPM/B23 S4 is likely to be carried out
by Plk2.
Since besides Plk2 also Plk4 regulates centriole duplication at
the G1/S-phase transition and in order to rule out that the NPM/
B23-S4 phosphorylation is also dependent on Plk4 in early S-
phase, we depleted Plk4 by RNAi from asynchronous and HU-
treated U2OS cells. However, in neither case, Plk4 siRNA
decreased the signal of NPM/B23-S4 phosphorylation (Fig. 5D)
suggesting that Plk4 cannot phosphorylate NPM/B23 at this site.
Taken together, our results point to a phosphorylation of NPM/
B23 on S4 by Plk1 in mitosis, while Plk2 catalyzes this
phosphorylation in S-phase.
NPM/B23 phosphorylation on S4 triggers centriole
duplication
NPM/B23 has been shown to specifically associate with the
unduplicated centrosome [11]. Upon Cdk2/Cyclin E-mediated
phosphorylation on T199 it dissociates from the centrosome to
allow centriole duplication [11][12]. In addition, Plk2 also triggers
centriole duplication [6][7]. To examine the role of phosphory-
lation of NPM/B23 on S4 in centriole duplication, we generated
in addition to the NPM/B23 S4A mutant also the NPM/B23
S4A/T199A double mutant and the phospho-mimicking mutants
S4D (D, aspartic acid) and S4E (E, glutamic acid). Equal
expression of the constructs is shown in Western blots in Fig. 6A.
These constructs were then used in a centrosome duplication
assay. This assay is based on the fact that in some cell lines, as for
example U2OS, DNA replication can be experimentally uncou-
pled from the centrosome cycle in the presence of DNA synthesis
inhibitors as HU or aphidicolin. This treatment allows multiple
rounds of centriole duplication to occur in the absence of DNA
replication or cytokinesis. In untreated cells, the vast majority of
U2OS cells contained 2 or 4 centrioles depending on the cell cycle
stage. In contrast, most aphidicolin-treated U2OS cells had
multiple centrioles (.4) (Fig. 6B right) [23]. To perform this
experiment we used a U2OS cell line that stably expressed GFP-
Figure 3. Plk2 phosphorylates NPM/B23 on serine 4. A Flag-NPM/B23 was overexpressed in 293T cells. After lysis, immunoprecipitations with
anti-Flag antibodies or random IgGs as control were performed. Immunoprecipitated Flag-NPM/B23 and controls were subjected to in vitro kinase
assays with Zz-Plk2 WT or KD, purified from bacteria, in the presence of [c
32P]-ATP. To assess Zz-Plk2 WT and KD kinase activity, in vitro kinase assays,
supplemented with [c
32P]-ATP, were performed using a-Casein as substrate. Kinase assays were resolved by SDS-PAGE. After Coomassie staining of
the gel, phosphorylation was detected by autoradiography. B To identify the Plk2 phosphorylation site on NPM/B23, in vitro kinase assays were
carried out using Zz-tagged Plk2 WT in combination with GST-tagged NPM/B23 fragments shown in Fig. 2G, as control GST alone, in the presence of
[c
32P]-ATP. After SDS-PAGE, followed by Coomassie blue staining of the gel, analysis was done by autoradiography. C To verify the NPM/B23
phosphorylation site, NPM/B23 serine 4 and threonine 95 were mutated to alanine (A). GST-NPM/B23 (aa 1–120) WT, S4A and T95A were incubated
with Zz-Plk2 in an in vitro kinase assay and analyzed as in (B). D In vitro kinase assay using immunoprecipitated Flag-NPM/B23 S125A mutant from
293T cells together with Zz-Plk2 WT and Zz-Plk2 KD from bacteria. Analysis was done as in (A). E In vitro kinase assay, assembled and analyzed as in
(A) besides using immunoprecipitated Flag-NPM/B23 WT, S4A or T199A as substrates. F In vitro kinase assay using immunoprecipitated Flag-Plk2 WT
or KD from 293T cells together with His-tagged NPM/B23 WT or S4A from bacteria. Reactions were subjected to Western blot analysis using anti-pS4
NPM/B23 and anti-NPM/B23 antibodies. G In vitro kinase assay, assembled and analyzed as described in (F) besides using GST-tagged Plk1 WT or KD.
doi:10.1371/journal.pone.0009849.g003
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9849Figure 4. Phosphorylation of NPM/B23 serine 4 is cell cycle regulated. A Cell extracts from HeLa cells, asynchronously (exp) grown or
synchronized in S-phase (S) by 4 mM hydroxyurea for 40 h or in M-phase (M) by 100 ng/ml nocodazole for 15 h, were examined by Western blotting
using the indicated antibodies. GAPDH, loading control. B Plk1 or Plk2 were immunoprecipitated from HeLa extracts, either exponentially grown or
arrested in M-phase or in S-phase as described in (A), and subjected to in vitro kinase assays using a-Casein as a substrate in the presence of [c
32P]-
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centrioles [24]. Results in Fig. 6B show that while NPM/B23 WT
interferes with centrosome reduplication (25% of the cells
exhibited the reduplication phenotype, i.e. .4 centrioles), this
effect was even more pronounced when the S4A mutant was
transfected (18% of cells with .4 centrioles). Interestingly,
transfection of the double mutant S4A/T199A had the strongest
effect with 11% of cells that contained .4 centrioles, which
suggests that these two phosphorylations collaborate to promote
centriole duplication. Together these results indicate that phos-
phorylation of NPM/B23 on S4 allows centriole reduplication.
The phospho-mimicking mutants NPM/B23 S4D and S4E did
not show an effect on aphidicolin-induced centriole reduplication
(Fig. 6B). To directly verify that a phosphorylation of NPM/B23
on S4 promotes centriole duplication, NPM/B23 mutants were
overexpressed in unperturbed U2OS GFP-Centrin1 cells. Our
findings shown in Fig. 6C (left panel) demonstrate again that
expression of NPM/B23 WT and the mutants S4A and S4A/
T199A led to an inhibition of centriole duplication resulting in a
dilution of centrioles in these cells. Interestingly, overexpression of
the phospho-mimicking mutants S4D or S4E did lead to an
increase of centriole numbers (Fig. 6C, right panel). This
demonstrates, that NPM/B23 in an unphosphorylated NPM/
B23 S4 state inhibits centriole reduplication as well as unperturbed
centriole duplication. In addition, we show that phosphorylation of
NPM/B23 S4 directly promotes centriole duplication in unper-
turbed cells. Since NPM/B23 S4 phosphorylation in S-phase
depends on Plk2 activity (Fig. 4 and 5), Plk2-mediated phosphor-
ylation of NPM/B23 seems to trigger centriole duplication.
To further demonstrate that Plk2 regulates centriole duplication
via NPM/B23 phosphorylation on S4 we again used a centrosome
duplication assay as described in Fig. 6B. To verify our results, we
Figure 5. NPM/B23 serine 4 phosphorylation in S-phase is mediated by Plk2. A Flag-Plk2 WT, KD or Flag-alone were overexpressed in 293T
cells. 8 h after transfections cells were arrested with 4 mM hydroxyurea (HU) for 40 h. Exponentially growing cells were harvested 48 h after
transfections. Cell extracts were analyzed by SDS-PAGE and Western blot using anti-Flag, anti-NPM/B23, anti-pS4 NPM/B23 and anti-a-Tubulin
(loading control) antibodies. B RNAi of Plk2 was mediated by overexpression of pSuper-RNAi-Plk2 and pSuper-RNAi-Luciferase as control in 293T cells.
Cell cycle synchronization and analyses were carried out as in (A). To detect Plk2 downregulation in Western blot, membranes were probed with anti-
Plk2 antibodies. C RNAi of Plk1 in HeLa cells was mediated by Lipofectamine2000-transfections of Plk1 specific siRNAs. GL2 siRNAs were used as
control. Cell extracts were analyzed by Western blotting with the indicated antibodies. Loading control, a-Tubulin. D Plk4 was downregulated in
U2OS cells by Lipofectamine2000 mediated siRNA transfections, as control GL2 was used. S-phase arrest was achieved as described in (A).
Downregulation of Plk4 and pS4 NPM/B23 levels were examined by Western blot analysis with the indicated antibodies. Loading control, a-Tubulin.
doi:10.1371/journal.pone.0009849.g005
ATP. For experimental details see in Fig. 3A. HC, IgG heavy chain. C Plk1 and Plk2 were immunoprecipitated from HeLa extracts as described in (B) and
subjected to in vitro kinase assays with His-tagged NPM/B23 as substrate. Western blotting was performed by NPM/B23 pS4 antibodies. Equal His-
NPM/B23 levels are shown by Ponceau S staining. D In vitro kinase assays using GST-tagged Plk1 and His-NPM/B23 were performed in the presence of
100 mM BI2536 or DMSO. Phosphorylation of His-NPM/B23 was detected by Western blot with anti-pS4 NPM/B23 antibodies. Loading control, NPM/
B23; unt., untreated. E In vitro kinase assays using immunoprecipitated Flag-Plk2 WT from 293T cells and His-NPM/B23 as substrate. The experiment
was performed as described in (D). F HeLa cells were incubated with 100 nM BI2536 or DMSO for 2 h. Cell extracts were used for
immunoprecipitations with anti-Plk1 or anti-Plk2 antibodies and subjected to in vitro kinase assays using a-Casein as substrate, supplemented with
[c
32P]-ATP. Kinase assays were analyzed as described in (B). G Asynchronous HeLa or U2OS cells or S-phase arrested HeLa cells as in (A) were treated
with 100 nM BI2536 for 2 h. Cell extracts were prepared for Western blotting with anti-NPM/B23 and anti-pS4 NPM/B23 antibodies. Loading control,
a-Tubulin. Quantifications of kinase activities or protein levels in this figure were generated by ImageJ (NIH).
doi:10.1371/journal.pone.0009849.g004
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9849Figure 6. Serine 4 phosphorylated NPM/B23 promotes centrosome duplication. A After transfections with Flag-tagged NPM/B23 WT and non-
phosphorylatable mutants (S4A, T199A, S4A/T199A) or phospho-mimicking mutants (S4D, S4E), centriole reduplication was performed in U2OS GFP-Centrin1
cells with 1.9 mg/ml aphidicolin for 75 h. Afterwards, cells were fixed for immunofluorescence and cells lysates were prepared for Western blot analysis using
anti-Flag antibodies to show comparable expression levels of the transfected constructs. Loading control, GAPDH. B Quantification of the centriole
reduplication phenotype of experiments described in (A). Cells were analyzed by immunofluorescence using anti-Flag antibodies to detect transfected cells.
Flag-positive cells were analyzed for centriole reduplication (.4 GFP-Centrin1 dots/centrioles). For quantification, .150 transfected cells were counted in three
independent experiments. Insets show representative centriole reduplication phenotypes. GFP-Centrin1, green. C Non-phosphorylatable or phospho-
mimicking Flag-tagged NPM/B23 mutants described in (A) were overexpressed in U2OS GFP-Centrin1 cells for 48 h. After immunofluorescence using anti-Flag
antibodies, Flag-positive cells were scored for centriole dilution (,2 GFP-Centrin1 dots/centrioles) or centriole amplification (4 or .4G F P - C e n t r i n 1d o t s /
centrioles). Quantifications are means +/2standard deviation from three independent experiments, .150 transfected cells were counted for each experiment.
doi:10.1371/journal.pone.0009849.g006
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only inhibits Plk2 since Plk1 is not active (Fig. 4B and 4C) and
therefore cannot affect NPM/B23 S4 phosphorylation at this cell
cycle stage (Fig. 5C). Treatment with the inhibitor reduced NPM/
B23-S4 phosphorylation by leaving overall levels of NPM/B23
unaltered (Fig. 7A). Furthermore, the inhibitor also interferes with
centriole reduplication since the reduplication phenotype (cells
with .4 centrioles) exhibited by around 50% of the cells was
reduced to 12% (Fig. 7B and 7C). Similar results were obtained
when centrosomes were stained with c-Tubulin. We then tested
whether the effect of BI2536 on centriole reduplication from Fig. 7
could be reversed by the overexpression of NPM/B23 mutants
used in Fig. 6. Fig. 8A demonstrates that U2OS GFP-Centrin1
cells that were transfected with NPM/B23 WT, S4A, S4D and
S4E mutants and arrested with aphidicolin showed a decreased
phosphorylation on S4 in the presence of the small molecule
inhibitor BI2536. Expression of the NPM/B23 WT or the S4A
mutant lead to reduced centrosome reduplication upon treatment
with the inhibitor, resulting in inhibition of Plk2 activity, to an
extent that was similar to control transfections. Importantly,
however, when the phospho-mimicking mutants NPM/B23 S4D
or S4E were transfected the reduplication phenotype could be
restored up to 2-fold in comparison to controls suggesting that
expression of these mutants can partially rescue the effects on
centriole duplication induced by BI2536 (Fig. 8B and 8C). Since
NPM/B23 WT had only a minimal effect, we anticipate that only
a small amount of the very abundant NPM/B23 protein in the
cells is indeed phosphorylated on S4.
As BI2536 also inhibits Plk1 kinase activity and to strengthen
the results obtained we used Plk2 siRNAs to specifically interfere
Figure 7. Treatment with BI2536, a Polo-kinase inhibitor, interferes with centriole reduplication. A U2OS GFP-Centrin1 cells were
treated with 1.9 mg/ml aphidicolin to induce centriole reduplication for 75 h. In parallel, treatment with 100 nM BI2536 or DMSO as control was
performed. Cell extracts were resolved by SDS-PAGE and analyzed on Western blot level with anti-NPM/B23 and anti-pS4 NPM/B23 antibodies. a-
Tubulin, loading control. B Indirect immunofluorescence analysis from the experiment described in (A) was carried out specific for c-Tubulin after
methanol fixation. Insets show enlargement of centrioles. GFP-Centrin1, green; c-Tubulin, red; DNA, blue. Scale bar, 10 mm. C For statistics, the
experiment in (B) was also scored for centriole reduplication (.4 GFP-Centrin1 dots/centrioles or .2 c-Tubulin dots/centrosomes) by microscopy. For
quantification, more than 200 cells were analyzed for centriole reduplication in three independent experiments. Black bars, GFP-Centrin1 signal; grey
bars, c-Tubulin staining; unt, untreated; aph, aphidicolin.
doi:10.1371/journal.pone.0009849.g007
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Centrin1 cells were transfected with NPM/B23 WT, S4A and S4E
mutants and arrested in S-phase by aphidicolin treatment. Down-
regulation of Plk2 is shown in Fig. 9A. While either NPM/B23
WT or S4A transfections did not restore the Plk2 siRNA reduction
of the reduplication phenotype, we found that expression of the
S4E mutant restored the phenotype (Fig. 9B and 9C). Taken
together, these results again show that Plk2-mediated phosphor-
ylation of NPM/B23 on S4 in S-phase promotes centriole
duplication.
Discussion
In this report, we set out to search for novel binding partners
and/or substrates of the kinase Plk2 in order to understand how
Plk2 triggers centrosome duplication. We have identified NPM/
B23 as a novel interacting protein of Plk2 and have shown that
both endogenous and exogenous Plk2 bind to NPM/B23.
Furthermore, we demonstrate that NPM/B23 is a substrate of
Plk2 in vivo and that phosphorylation by Plk2 occurs on serine 4 in
S-phase, which triggers centriole duplication.
NPM/B23 is a very abundant and highly conserved phospho-
protein that resides in the nucleoli, although it rapidly shuttles
between the nucleus and the cytoplasm [15]. By shuttling between
cellular compartments, NPM/B23 takes part in various cellular
processes including maintenance of genomic stability. Its phos-
phorylation state is modified by a number of protein kinases
during the cell cycle including casein kinase II [25] during
interphase. In mitosis, the localization of NPM/B23 is regulated
by kinases including Cdk1/Cyclin B [26], Nek2 [27] and Plk1
[14]. Before the cell enters mitosis, the interphase centrosome
duplicates which has to take place in coordination with other cell
cycle events including DNA synthesis. The process on how
initiation of centriole duplication occurs and how it is regulated is
not well understood. During S-phase, a new (daughter) centriole
grows from the lateral surface of each pre-existing (mother)
centriole, due to the combined influence of Cdk2/Cyclin E activity
and a conserved set of centriole assembly factors [2] [28][29]. In
contrast to disengagement in mitosis, new centriole growth occurs
in interphase and is dependent on Cdk2/Cyclin E [4]. NPM/B23
has been shown to associate to the unduplicated centrosome and
dissociates from it upon phosphorylation on T199 by Cdk2/Cyclin
E [11][12]. A NPM/B23 T199A mutant specifically inhibits
centrosome duplication [12]. Our own data demonstrate that
expression of a NPM/B23 S4A mutant also interferes with
centrosome duplication in both S-phase-arrested U2OS cells and
in an unperturbed U2OS cell cycle (Fig. 6B and 6C). Importantly,
we found that expression of NPM/B23 WT and S4A leads to a
loss of centrioles in these cells. Interestingly, a NPM/B23 T199A/
S4A double mutant further increased the effect suggesting that
both phosphorylations need to occur to obtain a pronounced effect
on centrosome duplication. This presumption is also supported by
the fact that Plk2 and Cdk2/Cyclin E are activated at the same
time in the cell cycle near the G1/S phase transition [6]. Plk1 can
also phosphorylate NPM/B23 on S4 in mitosis [14]. In S-phase,
Plk1 protein levels are low (Fig. 4A) since it becomes degraded
after cytokinesis by APC/Cdh1 [30] and is consequently not active
(Fig. 4B and 4C). Therefore, it is unlikely that Plk1 kinase activity
accounts for the phosphorylation on S4 in S-phase extracts. In
addition, a direct phosphorylation of NPM/B23 on S4 by Plk1 in
S-phase could be excluded by RNAi experiments (Fig. 5C). Recent
data suggest that Plk1 rather acts in coordination with separase to
control centriole disengagement at mitotic exit, which is a
prerequisite for centriole duplication to occur in S-phase [31].
Moreover, this work shows that Plk2 activity directly effects NPM/
B23 S4 phosphorylation in S-phase and that a phosphorylation of
NPM/B23 S4 promotes centriole duplication (Fig. 6C, left panel).
These data are particular strengthened by experiments presented
in Fig. 8 and 9 when we either used the small molecule inhibitor
BI2536 or Plk2 specific siRNAs in S-phase arrested cells to ablate
Plk2 function which leads to a reduction in the centriole
reduplication phenotype. In both setups the phospho-mimicking
mutant, S4E, could rescue the phenotype while the non-
phosphorylatable mutant S4A did not. Taken together, our results
demonstrate that centriole duplication in S-phase is positively
regulated by a phosphorylation of NPM/B23 on S4 by Plk2, a S-
phase linked Polo-like kinase.
Interestingly, Plk22/2 mice are viable [32]. We anticipate that
there might be a functional redundancy between polo-like kinases
in the early mouse development. Therefore, either Plk1 or Plk3,
which has been recently found to be involved in S-phase entry,
[33] could take over the function of Plk2 in centriole duplication.
Although Plk4 is a key trigger of centriole duplication [34][35]
we did not find that phosphorylation on NPM/B23 S4 was
dependent on Plk4 in vivo (Fig. 5G). Cdk2/Cyclin E seems to
collaborate with both Plk4 and Plk2 [7] [33]. It is therefore likely
that the two Polo-like kinases possess different substrate specific-
ities. This can be explained by their distinct structural properties in
particular the different Polo-boxes. Their different architectures
argue against a conservation of phosphoprotein binding function
since residues that are most involved in phosphopeptide binding
by Plk1 or Plk2 are not conserved in Plk4 [8][9].
In conclusion, Plk2 may contribute to aneuploidy and
tumorigenesis by uncontrolled phosphorylation of NPM/B23 on
S4 at the G1/S phase transition and thereby triggering centriole
reduplication. In fact, phosphorylation of NPM/B23 is increased
in several tumor cell lines including melanoma cell lines [36][37],
and is used as a marker of melanoma progression and aneuploidy
[37]. Thus phosphorylation of NPM/B23 on S4 by Plk2 provides
a novel mechanism that links centrosome duplication to
chromosomal instability and tumorigenesis.
Materials and Methods
Cell Culture, Synchronization and Transfection
HeLa, 293T, U2OS and U2OS GFP-Centrin1 (S.Duensing,
Pittsburgh) cells were cultured in DMEM (Sigma) containing 10%
fetal bovine serum (PPA), 5% of 200 mM L-glutamine (Invitrogen)
and if necessary 5% penicillin-streptomycin solution (Invitrogen) at
37uCi n5 %C O 2. Cells were synchronized in S-phase with 4 mM
Figure 8. Overexpression of phospho-mimicking NPM/B23 S4D and S4E mutants rescues BI2536-inhibited centriole reduplication.
A U2OS GFP-Centrin1 cells were transfected with Flag-NPM/B23 constructs for 8 h and then subjected to a centrosome duplication assay with 1.9 mg/
ml aphidicolin for 75 h. At the same time, cells were incubated either with 100 mM BI2536 or DMSO as control. Western blot analysis showing the
expression of all constructs and pS4 NPM/B23 protein levels. B After methanol fixation, indirect immunofluorescence analysis with anti-Flag
antibodies was performed. Insets show enlargements of centrioles. GFP-Centrin1, green; Flag, red; DNA, blue. Scale bar, 10 mm. C For statistics, U2OS
GFP-Centrin1 cells from indirect immunofluorescence analyses in (B) were scored for centriole reduplication (.4 GFP-Centrin1 dots/centrioles). In
case of transfections, only Flag-positive cells were analyzed. In total, 150 cells were counted each in 3 independent experiments to calculate means +/
2 standard deviation. unt, untreated; aph, aphidicolin.
doi:10.1371/journal.pone.0009849.g008
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were treated with 100 ng/ml nocodazole (Sigma) for 15 h.
Inhibition of Polo-kinase activity was achieved by a 2 h incubation
with 100 nM BI2536 (Boehringer Ingelheim). 293T cells were
transfected using calcium phosphate and HBS buffer (10 mM
HEPES pH 7.4, 140 mM NaCl, 3 mM EDTA). U2OS GFP-
Centrin1 cells were transfected with Lipofectamine2000 (Invitro-
gen) according to the manufacturers instructions for DNA
plasmids. SiRNA transfections and vector-mediated RNAi were
performed with Lipofectamine2000 (Invitrogen) as described
previously [6][7][15][38].
Recombinant protein production
Expression of recombinant proteins was carried out in E.coli
BL21 cells. After collecting bacterial cells, they were lysed in
50 mM Tris-HCl pH 7.5, 250 mM NaCl, 2 mM MgCl2,4m Mb-
mercaptoethanol, 5% glycerol, 0.4 mg/ml lysozyme (Sigma) for
30 min on ice and subjected to sonification. Following centrifu-
gation, the supernatant was incubated with glutathione agarose
(Sigma-Fluka) for GST-tagged proteins, or Ni-NTA agarose
(Biorad) for His-tagged proteins for 3 h at 4uC. After washing
the agarose three times, elution of proteins was performed with
either 20 mM reduced L-glutathione (Sigma) for GST-tagged
protein or with 300 mM imidazole (Sigma) for His-tagged
proteins.
Mass spectrometry analysis
EGFP-Plk2 immunoprecipitates were resolved by SDS-poly-
acrylamid gel electrophoresis (PAGE) and co-immunoprecipitating
proteins were detected in gel by silver staining. In-gel digestion and
mass spectrometric analysis was performed as described previously
[39]. In brief, protein bands of interest were cut out and digested
with trypsin after reduction and alkylation of cystines. Peptides
were separated by nanoHPLC and analyzed with an on-line
coupled ESI QTOF MS (Applied Biosystems). Only doubly and
triply charged ions were selected for fragmentation. The
uninterpreted MS/MS spectra were searched against the NCBInr
database, taxonomy human (191517 sequences, download
16.03.2007) using the Mascot software (Matrix Science). The
algorithm was set to use trypsin as enzyme, allowing at maximun
for one missed cleavage site and assuming carbamidomethyl as a
fixed modification of cysteine, and oxidized methionine and
deamidation of asparagines and glutamines as variable modifica-
tions. Mass tolerance was set to 0.1 Da for MS and MS/MS,
respectively. A significant threshold of p,0.05 has been used to
distinguish between correct and false peptide identifications.
Antibodies
anti-FlagM2, anti-a-Tubulin; anti-c-Tubulin [Sigma]; anti-Myc
(9E10), anti-Plk1 (F-8), anti-CyclinE (H-12), anti-GST [Santa-
Cruz], anti-NPM/B23 [Zymed]; anti-GAPDH, anti-GFP [Ab-
cam]; anti-pS4 NPM/B23, anti-pT199 NPM/B23 [Cell Signaling
Technology]; anti-NPM/B23 [M.Schmidt-Zachmann, DKFZ,
Heidelberg], anti-Plk2 CDL-21 [6], anti-Cyclin B1 [40], anti-
Plk4 [7].
Immunoprecipitations, Western blot analysis and Far
Western blot analysis
Cell extracts were prepared with lysis buffer (40 mM Tris-HCl
pH 7.5, 0.5% NP-40, 150 mM NaCl, 5 mM EDTA, 10 mM
b-glycerolphosphate, 5 mM NaF and protease inhibitor cocktail).
For immunoprecipitation, 3–5 mg cell extract were incubated
with 3–5 mg primary antibodies either for 2 h or for overnight at
4uC. 10 ml of seated Protein G sepharose (GE Healthcare) was
added and reactions were incubated for 1 h at 4uC. Immuno-
complexes were washed three times with lysis buffer and
examined by Western blot analysis. For Western blot analysis a
standard protocol was used [41][42]. Immunoreactive signals
were detected with ECL Western blotting substrate (Thermo
Scientific) or Super Signal West Dura Extended Duration Signal
(Thermo Scientific). Far Western blot analysis was carried out
using 250 ng of His-tagged NPM/B23 as bait and ligand binding
was performed in 5% milk powder in TBST (40 mM Tris-HCl
pH7.5, 300 mM NaCl, 0.2% Tween20), with 1 mg/ml GST-
Plk2-PBD, GST-Plk2-PBD mutant or GST alone for 6 h at 4uC.
Bound protein was then detected by Western blot analysis using
anti-GST antibodies.
Pulldown and In vitro binding assay
Zz-tagged proteins [43] were bound to IgG sepharose (GE
Healthcare) in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM
MgCl2,5 %g l y c e r o l ,1 0m Mb-glycerolphosphate, 5 mM NaF
and protease inhibitor cocktail. IgG sepharose was washed three
times and 10 mg HeLa extract was added followed by incubation
for 3 h at 4uC. After washing the sepharose beads again, bound
proteins were eluted with 200 mM NaCl followed by 1 M NaCl
and examined by Western blot analysis. For in vitro binding
assays either 25 mg GST-NPM/B23 bound to glutathione
agarose or immunoprecipitated Flag-Plk2 fragments bound to
Protein G sepharose were incubated with 8 ml in vitro translated
HA-Plk2 (TnT Reticulocyte Kit, Promega) and 15 mgr e c o m b i -
nant His-NPM/B23, respectively, in PBS containing 0.05% NP-
40 for 2 h at 4uC. After washing complexes three times with PBS
containing 0.05% NP-40, protein complexes were separated by
SDS-PAGE. Afterwards, radioactively labeled proteins were
detected after Coomassie blue staining by autoradiography while
non-radioactive binding assays were analyzed by Western blot
analysis.
In vitro kinase assay
To assay Plk1 and Plk2 kinase activities, immunoprecipitated or
bacterially expressed and purified kinases were incubated either
with immunoprecipitated proteins or 500 ng recombinant proteins
from bacteria as substrates and analyzed as described previously
[6]. Non-radioactive kinase assays were examined by Western blot
analysis using anti-pS4 NPM/B23 antibodies.
Figure 9. Overexpression of the phospho-mimicking NPM/B23 S4E mutant rescues inhibition of centriole reduplication induced by
Plk2 RNAi. A U2OS GFP-Centrin1 cells were subjected to siRNA transfections (siPlk2 or GL2 as control) using Lipofectamine2000, transfected with
Flag-NPM/B23 constructs for 8 h and then subjected to a centrosome duplication assay in the presence of 1.9 mg/ml aphidicolin for 75 h. Western
blot analysis demonstrated the downregulation of Plk2 by specific antibodies. loading control, a-Tubulin B After fixing cells from experiment in (A)
with methanol indirect immunofluorescence analyses were carried out with anti-Flag antibodies. Insets show enlargements of centrioles. GFP-
Centrin1, green; Flag, red; DNA, blue. Scale bar, 10 mm. C For statistics, U2OS GFP-Centrin1 cells from indirect immunofluorescence analyses in (B)
were scored for centriole reduplication (.4 GFP-Centrin1 dots/centrioles). In case of transfections, only Flag-positive cells were analyzed. In total, 200
cells were counted each in 3 independent experiments to calculate means +/2 standard deviation. unt, untreated, aph, aphidicolin.
doi:10.1371/journal.pone.0009849.g009
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After DNA transfections for 8 h, U2OS GFP-Centrin1 cells
were treated with 1.9 mg/ml aphidicolin (Sigma) for 75 h. Polo-
kinase inhibition by 100 nM BI2536 was carried out during
aphidicolin treatment. Plk2 RNAi was performed as described in
[7], after 20 h DNA transfections followed. Cells were then
subjected to immunofluorescence analysis.
Immunofluorescence microscopy
U2OS or U2OS GFP-Centrin1 cells on acid-washed coverslips
were fixed with 100% icecold methanol for 6 min at 220uC. After
blocking in 3% bovine serum albumin (Sigma) in PBS for 30 min,
primary antibody incubation (anti-FlagM2, anti-c-Tubulin [Sig-
ma]; anti-Plk2 CDL-21 [6]; anti-GT335 [Carsten Janke, CRBM,
Montpellier]) was carried out for 1 h at room temperature,
followed by a 30 min incubation with an secondary antibody (anti-
mouse Alexa594, anti-rabbit Alexa488 [Invitrogen]). DNA was
stained by Hoechst 33342 (Molecular probes). For imaging, the
Leica Leitz DMRBE microscope equipped with a Leica FWII
camera was used. Image processing was performed by ImageJ
(NIH).
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